Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024

NEWARK, Calif., Aug. 19, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation lawsuit against Actavis, Inc. related to Actavis's Abbreviated New Drug Application for generic versions of Depomed's Gralise® (gabapentin) tablets for the management of postherpetic neuralgia.

Judge Pisano's ruling finds that Actavis infringes all seven Depomed patents asserted and upholds the validity of the patents.  The latest expiration of the infringed patents is February 2024.

"We are pleased with this decision, as it confirms the innovation of Gralise and the strength of our patents.  This ruling provides for nearly 10 years of additional market exclusivity," commented Jim Schoeneck, President and Chief Executive Officer of Depomed.  "We look forward to providing Gralise to postherpetic neuralgia patients and their physicians well into the next decade."

Depomed previously announced settlements with two other Gralise ANDA filers providing for generic entry on January 1, 2024.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and CNS disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.